{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T23:25:44Z","timestamp":1780701944380,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institute of Health Research","doi-asserted-by":"crossref","award":["HBR-422155"],"award-info":[{"award-number":["HBR-422155"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-025-01986-0","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T12:22:50Z","timestamp":1756470170000},"page":"139-147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Experiences of people who inject drugs with hepatitis C testing and their perceptions of a pharmacy-based testing option: a qualitative study"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9003-5869","authenticated-orcid":false,"given":"Cathy","family":"Balsom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9842-5909","authenticated-orcid":false,"given":"Shawn","family":"Bugden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0314-9890","authenticated-orcid":false,"given":"Lois A.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3114-8123","authenticated-orcid":false,"given":"Deborah","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"1986_CR1","unstructured":"World Health Organization. Hepatitis C. Hepatitis C Fact Sheet 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Accessed 2 May 2024."},{"key":"1986_CR2","doi-asserted-by":"crossref","unstructured":"Public Health Agency of Canada. The hepatitis C epidemic in Canada: An overview of recent trends in surveillance, injection drug use, harm reduction and treatment, CCDR 47(12) 2021. https:\/\/www.canada.ca\/en\/public-health\/services\/reports-publications\/canada-communicable-disease-report-ccdr\/monthly-issue\/2021-47\/issue-12-december-2021\/hepatitis-c-canada-surveillance-injection-drug-use-harm-reduction-treatment.html. Accessed 12 Nov 2024.","DOI":"10.14745\/ccdr.v47i12a01"},{"key":"1986_CR3","unstructured":"CDC. Clinical Overview of Viral Hepatitis. Viral Hepatitis 2025. https:\/\/www.cdc.gov\/hepatitis\/hcp\/clinical-overview\/index.html. Accessed 4 Jun 2025."},{"key":"1986_CR4","unstructured":"World Health Organization. Global Health Sector Strategy on Viral Hepatitis, 2016\u20132021: Towards ending viral hepatitis. Geneva: 2016."},{"key":"1986_CR5","unstructured":"National Hepatitis C estimates, Canada, 2019, CCDR 48(11\/12) 2022. https:\/\/www.canada.ca\/en\/public-health\/services\/reports-publications\/canada-communicable-disease-report-ccdr\/monthly-issue\/2022-48\/issue-11-12-november-december-2022\/national-hepatitis-c-estimates-canada-2019.html. Accessed 1 May 2025."},{"key":"1986_CR6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.14745\/ccdr.v46i05a07","volume":"46","author":"J Tarasuk","year":"2020","unstructured":"Tarasuk J, Zhang J, Lemyre A, et al. National findings from the Tracks survey of people who inject drugs in Canada, phase 4, 2017\u20132019. CCDR. 2020;46:138\u201348. https:\/\/doi.org\/10.14745\/ccdr.v46i05a07.","journal-title":"CCDR"},{"key":"1986_CR7","unstructured":"Public Health Agency of Canada. Report On Hepatitis B and C Surveillance in Canada: 2019 2022. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/diseases-conditions\/report-hepatitis-b-c-canada-2019.html. Accessed 10 May 2025."},{"key":"1986_CR8","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1186\/s12889-023-16017-8","volume":"23","author":"CR Balsom","year":"2023","unstructured":"Balsom CR, Farrell A, Kelly DV. Barriers and enablers to testing for hepatitis C virus infection in people who inject drugs \u2013 a scoping review of the qualitative evidence. BMC Public Health. 2023;23:1038. https:\/\/doi.org\/10.1186\/s12889-023-16017-8.","journal-title":"BMC Public Health"},{"key":"1986_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3109\/09687637.2014.899988","volume":"21","author":"M Harris","year":"2014","unstructured":"Harris M, McDonald B, Rhodes T. Hepatitis c testing for people who inject drugs in the United Kingdom: Why is uptake so low? Drugs. Educ Prev Policy. 2014;21:333\u201342. https:\/\/doi.org\/10.3109\/09687637.2014.899988.","journal-title":"Drugs Educ Prev Policy"},{"key":"1986_CR10","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/jvh.12869","volume":"25","author":"M Harris","year":"2018","unstructured":"Harris M, Bonnington O, Harrison G, et al. Understanding hepatitis C intervention success\u2014Qualitative findings from the HepCATT study. J Viral Hepat. 2018;25:762\u201370. https:\/\/doi.org\/10.1111\/jvh.12869.","journal-title":"J Viral Hepat"},{"key":"1986_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7517-11-1","volume":"11","author":"JA Barocas","year":"2014","unstructured":"Barocas JA, Brennan MB, Hull SJ, et al. Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study. Harm Reduct J. 2014;11:1. https:\/\/doi.org\/10.1186\/1477-7517-11-1.","journal-title":"Harm Reduct J"},{"key":"1986_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.103019","volume":"88","author":"KM Ward","year":"2021","unstructured":"Ward KM, McCormick SD, Sulkowski M, et al. Perceptions of network based recruitment for Hepatitis C testing and treatment among persons who inject drugs: a qualitative exploration. Int J Drug Policy. 2021;88: 103019. https:\/\/doi.org\/10.1016\/j.drugpo.2020.103019.","journal-title":"Int J Drug Policy"},{"key":"1986_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/14659891.2019.1704076","volume":"25","author":"B Tofighi","year":"2020","unstructured":"Tofighi B, Lee JD, Sindhu SS, et al. Engagement in the Hepatitis C care continuum among people who use drugs. J Subst Use. 2020;25:343\u20139. https:\/\/doi.org\/10.1080\/14659891.2019.1704076.","journal-title":"J Subst Use"},{"key":"1986_CR14","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/jvh.13087","volume":"26","author":"NH Latham","year":"2019","unstructured":"Latham NH, Pedrana A, Doyle JS, et al. Community-based, point-of-care hepatitis C testing: perspectives and preferences of people who inject drugs. J Viral Hepat. 2019;26:919\u201322. https:\/\/doi.org\/10.1111\/jvh.13087.","journal-title":"J Viral Hepat"},{"key":"1986_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/jvh.13214","volume":"27","author":"C Phillips","year":"2020","unstructured":"Phillips C, Schulkind J, O\u2019Sullivan M, et al. Improving access to care for people who inject drugs: Qualitative evaluation of project ITTREAT-an integrated community hepatitis C service. J Viral Hepat. 2020;27:176\u201387. https:\/\/doi.org\/10.1111\/jvh.13214.","journal-title":"J Viral Hepat"},{"key":"1986_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.drugalcdep.2018.06.013","volume":"190","author":"MR Skeer","year":"2018","unstructured":"Skeer MR, Ladin K, Wilkins LE, et al. \u2018Hep C\u2019s like the common cold\u2019: Understanding barriers along the HCV care continuum among young people who inject drugs. Drug Alcohol Depend. 2018;190:246\u201354. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.06.013.","journal-title":"Drug Alcohol Depend"},{"key":"1986_CR17","unstructured":"Planned Parenthood Newfoundland and Labrador Sexual Health Centre. Hepatitis C 2020. https:\/\/www.plannedparenthoodnlshc.com\/uploads\/1\/0\/0\/3\/100308324\/hepatitis_c.pdf. Accessed 4 Jun 2025."},{"key":"1986_CR18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.14745\/ccdr.v44i78a03","volume":"44","author":"N Shehata","year":"2018","unstructured":"Shehata N, Austin T, Ha S, et al. Barriers to and facilitators of hepatitis C virus screening and testing: a scoping review. Can Commun Dis Rep. 2018;44:166\u201372. https:\/\/doi.org\/10.14745\/ccdr.v44i78a03.","journal-title":"Can Commun Dis Rep"},{"key":"1986_CR19","unstructured":"The APPROACH 2.0 Study. APPROACH n.d. https:\/\/www.approachstudy.ca\/about-us. Accessed 24 May 2023."},{"key":"1986_CR20","first-page":"74","volume":"133","author":"N Gauld","year":"2020","unstructured":"Gauld N, Perry J, Jackson C, et al. Feasibility and outcomes of a hepatitis C screening programme in community pharmacies. N Z Med J. 2020;133:74\u201383.","journal-title":"N Z Med J"},{"key":"1986_CR21","unstructured":"Buchanan R, Hassan-Hicks P, Noble K, et al. Integrating community pharmacy testing for hepatitis C with specialist care. The Pharmaceutical Journal n.d. https:\/\/pharmaceutical-journal.com\/article\/research\/integrating-community-pharmacy-testing-for-hepatitis-c-with-specialist-care. Accessed 22 Dec 2022."},{"key":"1986_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102489","volume":"69","author":"MJ Hayes","year":"2024","unstructured":"Hayes MJ, Beavon E, Traeger MW, et al. Viral hepatitis testing and treatment in community pharmacies: a systematic review and meta-analysis. eClinicalMedicine. 2024;69: 102489. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102489.","journal-title":"eClinicalMedicine"},{"key":"1986_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/jvh.13207","volume":"27","author":"R Buchanan","year":"2020","unstructured":"Buchanan R, Cooper K, Grellier L, et al. The testing of people with any risk factor for hepatitis C in community pharmacies is cost-effective. Journal of Viral Hepatitis. 2020;27:36\u201344. https:\/\/doi.org\/10.1111\/jvh.13207.","journal-title":"J Viral Hepat"},{"key":"1986_CR24","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.japh.2017.04.463","volume":"57","author":"BJ Dong","year":"2017","unstructured":"Dong BJ, Lopez M, Cocohoba J. Pharmacists performing hepatitis C antibody point-of-care screening in a community pharmacy: a pilot project. J Am Pharm Assoc.\n450 Association 2017;57:510\u20135. https:\/\/doi.org\/10.1016\/j.japh.2017.04.463.","journal-title":"J Am Pharm Assoc"},{"key":"1986_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.drugpo.2017.05.042","volume":"47","author":"A Radley","year":"2017","unstructured":"Radley A, Tait J, Dillon JF. DOT-C: a cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy. Int J Drug Policy. 2017;47:126\u201336.","journal-title":"Int J Drug Policy"},{"key":"1986_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3138\/jammi-2024-0010","volume":"9","author":"R Pr\u00e9vost","year":"2024","unstructured":"Pr\u00e9vost R, Roy-St-Pierre \u00c9, Idir K, et al. Hepatitis C screening in community pharmacies\u2014a feasibility and knowledge transfer study: PHARMA-C. J Assoc Med Microbiol Infect Dis Can. 2024;9:161\u201372. https:\/\/doi.org\/10.3138\/jammi-2024-0010.","journal-title":"J Assoc Med Microbiol Infect Dis Can"},{"key":"1986_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13722-021-00260-8","volume":"16","author":"JI Tsui","year":"2021","unstructured":"Tsui JI, Barry MP, Austin EJ, et al. \u2018Treat my whole person, not just my condition\u2019: qualitative explorations of hepatitis C care delivery preferences among people who inject drugs. Addict Sci Clin Pract. 2021;16:52. https:\/\/doi.org\/10.1186\/s13722-021-00260-8.","journal-title":"Addict Sci Clin Pract"},{"key":"1986_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3138\/canlivj-2023-0016","volume":"7","author":"M Selfridge","year":"2024","unstructured":"Selfridge M, Barnett T, Lundgren K, et al. \u2018I just never wanted them to feel uncomfortable\u2019: Barriers to pharmacy-based identification and treatment of hepatitis C in Victoria, Canada. Can Liver J. 2024;7:257. https:\/\/doi.org\/10.3138\/canlivj-2023-0016.","journal-title":"Can Liver J"},{"key":"1986_CR29","unstructured":"Fuchs D, Craddock S, Rodger D, et al. Micro-elimination of hepatitis C in a population of opioid substitution clients \u2013 successful task-shifting of testing and treatment to a community-based nurse\/pharmacist dyad, Can Liver J. 2020. p. 63."},{"key":"1986_CR30","doi-asserted-by":"publisher","first-page":"S324","DOI":"10.1016\/S0168-8278(20)31150-8","volume":"73","author":"N Palmer","year":"2020","unstructured":"Palmer N, John P, Rockey K, et al. THU377 - Testing and treatment for hepatitis C in the community pharmacy setting: an opportunity not to be missed?. J Hepatol. 2020;73:S324. https:\/\/doi.org\/10.1016\/S0168-8278(20)31150-8.","journal-title":"J Hepatol"},{"key":"1986_CR31","unstructured":"Campbell M. Popular Names in Canada (Ontario and BC). Behind the Name n.d. https:\/\/www.behindthename.com\/top\/lists\/canada\/1983. Accessed 13 Jan 2023."},{"key":"1986_CR32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/2159676X.2019.1704846","volume":"13","author":"V Braun","year":"2021","unstructured":"Braun V, Clarke V. To saturate or not to saturate? Questioning data saturation as a useful concept for thematic analysis and sample-size rationales. Qual Res Sport Exerc Health. 2021;13:201\u201316. https:\/\/doi.org\/10.1080\/2159676X.2019.1704846.","journal-title":"Qual Res Sport Exerc Health"},{"key":"1986_CR33","unstructured":"Kelly D. APPROACH 2.0: HIV, HCV and syphilis testing through pharmacies. clinicaltrials.gov; 2024."},{"key":"1986_CR34","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1186\/s12889-020-08719-0","volume":"20","author":"DV Kelly","year":"2020","unstructured":"Kelly DV, Kielly J, Hughes C, et al. Expanding access to HIV testing through Canadian community pharmacies: findings from the APPROACH study. BMC Public Health. 2020;20:639. https:\/\/doi.org\/10.1186\/s12889-020-08719-0.","journal-title":"BMC Public Health"},{"key":"1986_CR35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.drugpo.2016.09.004","volume":"39","author":"AB Collins","year":"2017","unstructured":"Collins AB, Strike C, Guta A, et al. \u201cWe\u2019re giving you something so we get something in return\u201d: perspectives on research participation and compensation among people living with HIV who use drugs. Int J Drug Policy. 2017;39:92\u20138. https:\/\/doi.org\/10.1016\/j.drugpo.2016.09.004.","journal-title":"Int J Drug Policy"},{"key":"1986_CR36","volume-title":"Thematic analysis: a practical guide","author":"V Braun","year":"2021","unstructured":"Braun V, Clarke V. Thematic analysis: a practical guide. SAGE Publications Ltd.; 2021."},{"key":"1986_CR37","first-page":"191","volume-title":"Routledge handbook of qualitative research in sport and exercise","author":"V Braun","year":"2016","unstructured":"Braun V, Clarke V, Weate P. Using thematic analysis in sport and exercise research. In: Routledge handbook of qualitative research in sport and exercise. London: Routledge; 2016. p. 191\u2013205."},{"key":"1986_CR38","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19:349\u201357. https:\/\/doi.org\/10.1093\/intqhc\/mzm042.","journal-title":"Int J Qual Health Care"},{"key":"1986_CR39","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S2468-1253(20)30120-5","volume":"5","author":"A Radley","year":"2020","unstructured":"Radley A, de Bruin M, Inglis SK, et al. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial. Lancet Gastroenterol Hepatol. 2020;5:809\u201318. https:\/\/doi.org\/10.1016\/S2468-1253(20)30120-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1986_CR40","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1111\/apt.16953","volume":"55","author":"CJ Byrne","year":"2022","unstructured":"Byrne CJ, Radley A, Inglis SK, et al. Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial. Aliment Pharmacol Ther. 2022;55:1512\u201323. https:\/\/doi.org\/10.1111\/apt.16953.","journal-title":"Aliment Pharmacol Ther"},{"key":"1986_CR41","volume-title":"Rapid synthesis: identifying pharmacist remuneration models for the provision of clinical services","author":"C V\u00e9lez","year":"2022","unstructured":"V\u00e9lez C, Bhuiya A, Wilson M. Rapid synthesis: identifying pharmacist remuneration models for the provision of clinical services. Hamilton: McMaster Health Forum; 2022."},{"key":"1986_CR42","volume-title":"Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization; 2018."},{"key":"1986_CR43","unstructured":"Public Health Agency of Canada. Addressing stigma: towards a more inclusive health system. Ottawa, ON. 2019."}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01986-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-01986-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01986-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:18:59Z","timestamp":1768972739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-01986-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["1986"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-01986-0","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}